Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
Status:
Completed
Trial end date:
2017-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in
opioid-experienced patients with moderate-to-severe chronic noncancer pain.